Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Scandinavian Journal of Urology and Nephrology

Volumn 36, Issue 6, 2002, Pages 405-413

  Hedlund, Per Olov ^a,l   Ala Opas, Martti ^b   Brekkan, Einar ^c   Damber, Jan Erik ^d   Damber, Lena ^e   Hagerman, Inger ^a   Haukaas, Svein ^f   Henriksson, Peter ^a   Iversen, Peter ^g   Pousette, Åke ^a   Rasmussen, Finn ^h   Salo, Jaakko ⁱ   Vaage, Sigmund ^j   Varenhorst, Eberhard ^k   Krarup, Torben ^m   Hvidt, Valdemar ^m   Mogensen, Peter ^m   Luke, Michael ^m   Sörensen, Ole ^m   Frimodt Möller, Cai ^m   Willumsen, Henrik ^m   Klarskov, Peter ^m   Mortensen, Svend ^m   Andersen, Jesper Rye ^m   Rosenkilde, Palle ^m   Jensen, Hans Georg ^m   Larsen, Erik ^m   Skaarup, Paul ^m   Farber, John ^m   Melchior Nissen, Hans ^m   Mommsen, Sören ^m   Kristensen, Jörgen Kvist ^m   Wolf, Hans ^m   Lundbeck, Finn ^m   Höjsgaard, Arne ^m   Halme, Antero ^m   Ruutu, Mirja ^m   Kasinen, Eero ^m   Juusela, Harri ^m   Salminen, Risto ^m   Liukkonen, Tapani ^m   Viitanen, Jouko ^m   Talja, Martti ^m   Permi, Jaakko ^m   Puolakka, Veli Matti ^m   Nurmi, Martti ^m   Hansson, Erkki ^m   Geirsson, Gudmundur ^m   Höisaeter, Per Aage ^m   Hesselberg, Fredrik ^m   Vada, Karsten ^m   Tasdemir, Ilker ^m   Lundmo, Per ^m   Ögreid, Per ^m   Ribbegren, Carl Johan ^m   Owczarski, Andrzej ^m   Lindeborg, Torsten ^m   Borck, Leif ^m   Susskind, Stig ^m   Hedberg, Bo ^m   Jan Olof Olsson, Björn Kihl ^m   Häggarth, Lars ^a   Larsson, Bruno ^m   Lindberg, Bengt ^m   Carlsson, Sture ^m   Höjgaard, Inge ^m   Spångberg, Anders ^m   Elfving, Peter ^m   Lundgren, Rolf ^m   Hahne, Bengt ^m   Ideström, Rickard ^m   Hedelin, Hans ^d   Andersson, Bengt ^m   Sandin, Torsten ^m   Wallden, Mauritz ^m   Telhammar, Ebbe ^m   Olsson, Ronnie ^m   Granfors, Torvald ^m   Stattin, Per ^m   Johan Norlen, Bo ^m   Hammarsten, Jan ^m   Mikkelsen, Ib ^m   Ramsing, Anders ^m   Wall, Inger ^m   Adell, Lars ^m   Ullman, Agneta ^m   Nelson, Curt Eric ^m   Ljungeryd, Susanne ^m   Andersson, Sven Olof ^m   Johansson, Jan Erik ^m   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f Diakonissehjemmet Hospital   (Norway)

^g Rigshospitalet   (Denmark)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j Stavanger Hospital   (Norway)

^k Norrköping Hospital   (Sweden)

^l Norrköping Hospital ^*  (Sweden)

^m Karolinska Hospital ^*

more..

Author keywords

Advanced disease; Cardiovascular complications; Combined androgen deprivation; Hormone treatment; Multicenter study; Parenteral estrogen; Prostate cancer

Indexed keywords

ESTROGEN; FLUTAMIDE; POLYESTRADIOL PHOSPHATE; TRIPTORELIN;

AGED; ALLERGY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FLUSHING; GYNECOMASTIA; HEART FAILURE; HUMAN; IMPOTENCE; ISCHEMIC HEART DISEASE; LIVER METABOLISM; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; ORCHIECTOMY; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTRADIOL CONGENERS; FLUTAMIDE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TRIPTORELIN;

EID: 0036973520     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655902762467549     Document Type: Article

References (22)

1. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282-5.
2. Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS. High dose polyestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989; 63: 512-4.
3. Lukkarinen O, Kontturi M, and the Finnish Zoladex Multicentre Study Group. Comparison of a long-acting LHRH agonist and polyestradiol phosphate in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 1994; 28: 171-8.
4. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 1989; 14: 183-8.
5. Henriksson P, Carlstrom K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, et al. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate 1999; 40: 76-82.
6. Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, et al. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988; 13: 257-61.
7. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000; 55: 328-33.
8. Esposti P. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol 1971; 5: 199-209.
9. Mostofi FK, Sesterhenn IA, Sobin LH. In: Histologic typing of prostate tumors. Geneva, Switzerland: edn World Health Organization, 1980: 17-21.
10. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017-21.
11. Andersson L. Design of clinical trials on prostate cancer. Urology 1997; 49 (Suppl 4A): 39-45.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
13. Frödin T, Ålund G, Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 1985; 7: 203-8.
14. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharrn 1987; 15: 657-80.
15. Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study, Finnprostate Group. Br J Urol 1998; 82: 63-8.
16. Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A, Vesterquist O, Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989; 3: 219-25.
17. Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988; 49: 111-21.
18. Hedlund PO, Gustafson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt®) or conventional estrogen. Scand J Urol Nephrol Suppl 1980; 55: 103.
19. Eisen M, Napp HE, Vock R. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate. J Urol 1975; 114: 93-7.
20. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281.
21. Cox RL, Crawford D. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-8.
22. Spetz AC, Hammar M, Lindberg B, Spångberg S, Varenhorst E. Prospective evaluation of hot flushes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001; 166: 517-20